


Gene therapy using CAR T-cells could provide long-term protection against HIV

December 28 2017



Scott Kitchen, the study's senior author Credit: UCLA Health

Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. These engineered cells not only destroyed the infected cells, they persisted for more than two years, suggesting the



potential to create long-term immunity from the virus that causes AIDS.

Antiviral drugs can suppress the amount of HIV in the body to nearly undetectable levels, but only an effective immune response can eradicate the virus. Researchers have been seeking a way to improve the body's ability to combat the virus by engineering blood-forming stem <u>cells</u> to specifically target and kill HIV-<u>infected cells</u> for the life of the individual. Although chimeric antigen receptor (CAR) T-cells have emerged as a powerful immunotherapy for various forms of cancer - and show promise in treating HIV-1 infection - the therapy may not impart long-lasting immunity. Researchers, physicians and patients need T cellbased products that can respond to malignant or infected cells that may reappear months or years after treatment.

Because HIV uses CD4 to infect cells, the researchers used a CAR molecule that hijacks the essential interaction between HIV and the cell surface molecule CD4 to make stem cell-derived T-cells target infected cells. When the CD4 on the CAR molecule binds to HIV, other regions of the CAR molecule signal the cell to become activated and kill the HIV infected cell. The researchers found that, in test animals, modification of the blood-forming stem cells resulted in more than two years of stable production of CAR-expressing cells without any adverse effects. In addition, these cells were widely distributed throughout the lymphoid tissues and gastrointestinal tract, which are major anatomic sites for HIV replication and persistence in infected people. Most important, engineered CAR T-cells showed efficacy in attacking and killing HIV-infected cells.

These findings are the first to show that <u>blood-forming stem cells</u> can be modified with a CAR therapy that can safely engraft in the bone marrow, mature and become functional immune cells throughout the body. This could lead to the development of an approach allowing for safe, lifelong immunity to HIV. Such an approach is likely to work best



when performed in combination with other treatment strategies, such as antiretroviral therapy. Researchers hope that this type of therapy could reduce infected individuals' dependence on antiviral medications, lower the cost of <u>therapy</u>, and permit the possible eradication of HIV from its hiding places in the body. The approach also has potential against other infections or malignancies.

The study will be published in the peer-reviewed PLOS Pathogens.

Provided by University of California, Los Angeles

Citation: Gene therapy using CAR T-cells could provide long-term protection against HIV (2017, December 28) retrieved 20 April 2024 from <u>https://medicalxpress.com/news/2017-12-gene-therapy-car-t-cells-long-term.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.